The Experts below are selected from a list of 6633 Experts worldwide ranked by ideXlab platform
Plamen Atanassov - One of the best experts on this subject based on the ideXlab platform.
-
a family of fe n c oxygen reduction electrocatalysts for microbial fuel cell mfc application relationships between surface chemistry and performances
Applied Catalysis B-environmental, 2017Co-Authors: Carlo Santoro, Alexey Serov, Rohan Gokhale, Santiago Rojascarbonell, Lydia Stariha, Jonathan Gordon, Kateryna Artyushkova, Plamen AtanassovAbstract:Abstract Different iron-based cathode catalysts have been studied for oxygen reduction reaction (ORR) in neutral media and then applied into microbial fuel cells (MFC). The catalysts have been synthesized using sacrificial support method (SSM) using eight different organic precursors named Niclosamide, Ricobendazole, Guanosine, Succinylsulfathiazole, Sulfacetamide, Quinine, Sulfadiazine and Pyrazinamide. Linear Sweep Voltammetry (LSV) curves were obtained for the catalysts using a O 2 saturated in 0.1 M potassium phosphate buffer and 0.1 M KCl solution and a Rotating Ring Disk Electrode (RRDE) setup in order to study the ORR characteristics. Additionally, we analyze the peroxide yield obtained for each catalyst which helps us determine the reaction kinetics. Those catalysts have been mixed with activated carbon (AC), carbon black (CB) and PTFE and pressed on a metallic mesh forming a pellet-like gas diffusion electrode (GDE). Results showed that Fe-Ricobendazole, Fe-Niclosamide and Fe-Pyrazinamide had the highest cathode polarization curves and highest power densities output that was above 200 μWcm −2 . Fe-Ricobendazole, Fe-Niclosamide, Fe-Pyrazinamide, Fe-Guanosine Fe-Succinylsulfathiazole and Fe-Sulfacetamide outperformed compared to Pt cathode. Fe-Sulfadiazene and Fe-Quinine performed better than AC used as control but less than Pt. Correlation of surface composition with performance showed that power density achieved is directly related to the total amount of nitrogen, and in particularly, N coordinated to metal and pyridinic and pyrrolic types while larger amounts of graphitic nitrogen result in worse performance.
J M D Galama - One of the best experts on this subject based on the ideXlab platform.
-
in vitro effects of Sulfadiazine and its metabolites alone and in combination with pyrimethamine on toxoplasma gondii
Antimicrobial Agents and Chemotherapy, 1995Co-Authors: Schoondermarkvan E De Ven, T B Vree, Willem J G Melchers, W Camps, J M D GalamaAbstract:Sulfadiazine and the metabolites N4-acetyl-Sulfadiazine, 4-OH-Sulfadiazine, 5-OH-Sulfadiazine, 5-OH-glucuronide-Sulfadiazine, and 5-OH-sulfate-Sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro. Except for N4-acetyl-Sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. The addition of 0.05 micrograms of pyrimethamine per ml, a concentration which in itself is not inhibitory, potentiated the microbial activity of Sulfadiazine and its metabolites 100 fold.
-
study of treatment of congenital toxoplasma gondii infection in rhesus monkeys with pyrimethamine and Sulfadiazine
Antimicrobial Agents and Chemotherapy, 1995Co-Authors: Schoondermarkvan E De Ven, T B Vree, W Camps, J M D Galama, I Baars, T K A B Eskes, J Meuwissen, Willem J G MelchersAbstract:The efficacy of the combination of pyrimethamine and Sulfadiazine for the treatment of congenital Toxoplasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and Sulfadiazine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for Sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine. Ten monkeys were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of Sulfadiazine per kg of body weight per day orally. The therapy was supplemented with 3.5 mg of folinic acid once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for Sulfadiazine. In addition, pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times higher than the corresponding concentrations in serum. Thirty percent of the Sulfadiazine was found to reach the brain tissue when compared with the corresponding serum concentration. when administered early after the onset of infection, the combination of pyrimethamine and Sulfadiazine was clearly effective in reducing the number of parasites in the fetus to undetectable levels.
Stephen O. Heard - One of the best experts on this subject based on the ideXlab platform.
-
anti infective external coating of central venous catheters a randomized noninferiority trial comparing 5 fluorouracil with chlorhexidine silver Sulfadiazine in preventing catheter colonization
Critical Care Medicine, 2010Co-Authors: Matthias J Walz, Kent L Carter, Karen J. Longtine, Rafael Linard Avelar, Leonard A. Mermel, Stephen O. HeardAbstract:Objective: The antimetabolite drug, 5-fluorouracil, inhibits microbial growth. Coating of central venous catheters with 5-fluorouracil may reduce the risk of catheter infection. Our objective was to compare the safety and efficacy of central venous catheters externally coated with 5-fluorouracil with those coated with chlorhexidine and silver Sulfadiazine. Design: Prospective, single-blind, randomized, active-controlled, multicentered, noninferiority trial. Setting: Twenty-five US medical center intensive care units. Patients: A total of 960 adult patients requiring central venous catheterization for up to 28 days. Interventions: Patients were randomized to receive a central venous catheter externally coated with either 5-fluorouracil (n 480) or chlorhexidine and silver Sulfadiazine (n 480). Measurements and Main Results: The primary antimicrobial outcome was a dichotomous measure ( 15 colony-forming units) for catheter colonization determined by the roll plate method. Secondary antimicrobial outcomes included local site infection and catheter-related bloodstream infection. Central venous catheters coated with 5-fluorouracil were noninferior to chlorhexidine and silver Sulfadiazine coated central venous catheters with respect to the incidence of catheter colonization (2.9% vs. 5.3%, respectively). Local site infection occurred in 1.4% of the 5-fluorouracil group and 0.9% of the chlorhexidine and silver Sulfadiazine group. No episode of catheter-related bloodstream infection occurred in the 5-fluorouracil group, whereas two episodes were noted in the chlorhexidine and silver Sulfadiazine group. Only Gram-positive organisms were cultured from 5-fluorouracil catheters, whereas Gram-positive bacteria, Gram-negative bacteria, and Candida were cultured from the chlorhexidine and silver Sulfadiazine central venous catheters. Adverse events were comparable between the two central venous catheter coatings. Conclusions: Our results suggest that central venous catheters externally coated with 5-fluorouracil are a safe and effective alternative to catheters externally coated with chlorhexidine and silver Sulfadiazine when used in critically ill patients. (Crit Care Med 2010; 38:2095–2102)
Schoondermarkvan E De Ven - One of the best experts on this subject based on the ideXlab platform.
-
in vitro effects of Sulfadiazine and its metabolites alone and in combination with pyrimethamine on toxoplasma gondii
Antimicrobial Agents and Chemotherapy, 1995Co-Authors: Schoondermarkvan E De Ven, T B Vree, Willem J G Melchers, W Camps, J M D GalamaAbstract:Sulfadiazine and the metabolites N4-acetyl-Sulfadiazine, 4-OH-Sulfadiazine, 5-OH-Sulfadiazine, 5-OH-glucuronide-Sulfadiazine, and 5-OH-sulfate-Sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro. Except for N4-acetyl-Sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. The addition of 0.05 micrograms of pyrimethamine per ml, a concentration which in itself is not inhibitory, potentiated the microbial activity of Sulfadiazine and its metabolites 100 fold.
-
study of treatment of congenital toxoplasma gondii infection in rhesus monkeys with pyrimethamine and Sulfadiazine
Antimicrobial Agents and Chemotherapy, 1995Co-Authors: Schoondermarkvan E De Ven, T B Vree, W Camps, J M D Galama, I Baars, T K A B Eskes, J Meuwissen, Willem J G MelchersAbstract:The efficacy of the combination of pyrimethamine and Sulfadiazine for the treatment of congenital Toxoplasma gondii infection in rhesus monkeys was studied. The dosage regimen for pyrimethamine and Sulfadiazine was established by pharmacokinetic studies in two monkeys. Those studies showed that the distributions of both drugs followed a one-compartment model. The serum elimination half-lives were found to be 5.2 h for Sulfadiazine and 44.4 h for pyrimethamine. Sulfadiazine reached a maximum concentration in serum of 58.7 micrograms/ml, whereas a maximum concentration in serum of 0.22 micrograms/ml was found for pyrimethamine. Ten monkeys were infected intravenously with T. gondii at day 90 of pregnancy, which is comparable to the second trimester of organogenetic development in humans. Treatment was administered to six monkeys, in whose fetuses infection was diagnosed antenatally. From the moment that fetal infection was proven, the monkeys were treated throughout pregnancy with 1 mg of pyrimethamine per kg of body weight per day and 50 mg of Sulfadiazine per kg of body weight per day orally. The therapy was supplemented with 3.5 mg of folinic acid once a week. No toxic side effects were found with this drug regimen. The parasite was no longer detectable in the next consecutive amniotic fluid sample, taken 10 to 13 days after treatment was started. Furthermore, T. gondii was also not found in the neonate at birth. The parasite was still present at birth in three of four untreated fetuses that served as controls. Both drugs crossed the placenta very well. Concentrations in fetal serum varied from 0.05 to 0.14 micrograms/ml for pyrimethamine and from 1.0 to 5.4 micrograms/ml for Sulfadiazine. In addition, pyrimethamine was found to accumulate in the brain tissue, with concentrations being three to four times higher than the corresponding concentrations in serum. Thirty percent of the Sulfadiazine was found to reach the brain tissue when compared with the corresponding serum concentration. when administered early after the onset of infection, the combination of pyrimethamine and Sulfadiazine was clearly effective in reducing the number of parasites in the fetus to undetectable levels.
Pornprom Muangman - One of the best experts on this subject based on the ideXlab platform.
-
randomized controlled trial of polyhexanide betaine gel versus silver Sulfadiazine for partial thickness burn treatment
The International Journal of Lower Extremity Wounds, 2017Co-Authors: Saruta Wattanaploy, Kusuma Chinaroonchai, Nantaporn Namviriyachote, Pornprom MuangmanAbstract:Silver Sulfadiazine is commonly used in the treatment of partial-thickness burns, but it sometimes forms pseudo-eschar and delays wound healing. Polyhexanide/betaine gel, a new wound cleansing and moisturizing product, has some advantages in removing biofilm and promotes wound healing. This study was designed to compare clinical efficacy of polyhexanide/betaine gel with silver Sulfadiazine in partial-thickness burn treatment. From September 2013 to May 2015, 46 adult patients with partial-thickness burn ≥10% total body surface area that were admitted to the Burn Unit of Siriraj Hospital within 48 hours after injury were randomly allocated into 2 groups. One group was treated with polyhexanide/betaine gel, and the other group was treated with silver Sulfadiazine. Both groups received daily dressing changes and the same standard care given to patients with burns in this center. Healing times in the polyhexanide/betaine gel group and silver Sulfadiazine group were 17.8 ± 2.2 days and 18.8 ± 2.1 days, respectively ( P value .13). There were no significant differences in healing times, infection rates, bacterial colonization rates, and treatment cost in both groups. The pain score of the polyhexanide/betaine gel group was significantly less than the silver Sulfadiazine group at 4 to 9 days after treatment ( P < .001). The satisfactory assessment result of the polyhexanide/betaine gel group was better than that in the silver Sulfadiazine group. These data indicate the need for adequately designed studies to elicit the full potential of polyhexanide gel as a wound dressing for partial-thickness burn wounds.
-
Benefit of Hydrocolloid SSD Dressing in the Outpatient Management of Partial Thickness Burns
2015Co-Authors: Pornprom Muangman, Saipin Muangman, Supaporn Opasanon, Kris Keorochana, Chomchark ChuntrasakulAbstract:Silver Sulfadiazine has been used as topical medication in the treatment of partial-thickness burns or secondary degree burns for many years. Pain during daily wound cleansing is the main problem. Urgotul SSDTM, a hydrocolloid dressing with silver Sulfadiazine (SSD) has been reported to reduce infection and exhibit antimicrobial activity in burn wounds. The purpose of the present study was to compare the efficacy of Urgotul SSDTM and 1 % silver Sulfadiazine for treatment of partial thickness burn wounds. The authors reviewed 68 patients who had partial thickness burn wound less than 15 % total body surface area (TBSA%) and were treated at Siriraj outpatient burn clinic during July 2005-December 2006. All patients were divided into two groups: Urgotul SSDTM treated group (34 patients) and 1 % silver Sulfadiazine treated group (34 patients). The two groups were compared by the demographic data including age, gender, % total body surface area (TBSA) burn, % TBSA deep burn, type of burn as well as percent of wound infection, total cost of wound dressing, pain medication, level of pain and time of wound healing. There were no differences in demographic data of age, % TBSA burn, % wound infection, total treatment cost of burn wound care (52 + 38 US $ for Urgotul SSDTM versus 45 + 34 US $ for silver Sulfadiazine treated group). Time of wound closure was significantly shorter in the Urgotul SSDTM treated group (10 + 4 days in Urgotul SSDTM versus 12 + 6 in 1% silver Sulfadiazine treated group) between both groups (p < 0.05). Average pain scores and pain medicatio
-
silk sericin ameliorates wound healing and its clinical efficacy in burn wounds
Archives of Dermatological Research, 2013Co-Authors: Pornanong Aramwit, Sirinoot Palapinyo, Teerapol Srichana, Suthat Chottanapund, Pornprom MuangmanAbstract:The aim of this study was to evaluate the effect of silk sericin, a protein from silkworm cocoon, on scratch wound healing in vitro. For applicable result in clinical use, we also study the efficacy of sericin added to a standard antimicrobial cream, silver zinc Sulfadiazine, for open wound care in the treatment of second-degree burn wounds. In vitro scratch assays show that sericin at concentration 100 μg/mL can promote the migration of fibroblast L929 cells similar to epidermal growth factor (positive control) at 100 μg/mL. After 1 day of treatment, the length of scratch in wounds treated with sericin was significantly shorter than the length of negative control wounds (culture medium without sericin). For clinical study, a total of 29 patients with 65 burn wounds which covered no less than 15 % of total body surface area were randomly assigned to either control (wounds treated with silver zinc Sulfadiazine cream) or treatment (wounds treated with silver zinc Sulfadiazine with added sericin cream) group in this randomized, double-blind, standard-controlled study. The results showed that the average time to reach 70 % re-epithelialization of the burned surface and complete healing in the treatment group was significantly shorter, approximately 5–7 days, than in the control group. Regarding time for complete healing, control wounds took approximately 29.28 ± 9.27 days, while wounds treated with silver zinc Sulfadiazine with added sericin cream took approximately 22.42 ± 6.33 days, (p = 0.001). No infection or severe reaction was found in any wounds. This is the first clinical study to show that silk sericin is safe and beneficial for burn wound treatment when it is added to silver Sulfadiazine cream.
-
benefit of hydrocolloid ssd dressing in the outpatient management of partial thickness burns
Journal of the Medical Association of Thailand Chotmaihet thangphaet, 2009Co-Authors: Pornprom Muangman, Saipin Muangman, Supaporn Opasanon, Kris Keorochana, Chomchark ChuntrasakulAbstract:Silver Sulfadiazine has been used as topical medication in the treatment of partial-thickness burns or secondary degree burns for many years. Pain during daily wound cleansing is the main problem. Urgotul SSD, a hydrocolloid dressing with silver Sulfadiazine (SSD) has been reported to reduce infection and exhibit antimicrobial activity in burn wounds. The purpose of the present study was to compare the efficacy of Urgotul SSD and 1% silver Sulfadiazine for treatment of partial thickness burn wounds. The authors reviewed 68 patients who had partial thickness burn wound less than 15% total body surface area (TBSA%) and were treated at Siriraj outpatient burn clinic during July 2005-December 2006. All patients were divided into two groups: Urgotul SSD treated group (34 patients) and 1% silver Sulfadiazine treated group (34 patients). The two groups were compared by the demographic data including age, gender, % total body surface area (TBSA) burn, % TBSA deep burn, type of burn as well as percent of wound infection, total cost of wound dressing, pain medication, level of pain and time of wound healing. There were no differences in demographic data of age, % TBSA burn, % wound infection, total treatment cost of burn wound care (52 +/- 38 US$ for Urgotul SSD versus 45 +/- 34 US$ for silver Sulfadiazine treated group). Time of wound closure was significantly shorter in the Urgotul SSD treated group (10 +/- 4 days in Urgotul SSD versus 12 +/- 6 in 1% silver Sulfadiazine treated group) between both groups (p < 0.05). Average pain scores and pain medication in Urgotul SSD treated group was significantly lower than 1% silver Sulfadiazine treated group (3 +/- 1 versus 6 +/- 2 and respectively, p < 0.05). All of the patients who developed wound infection responded well to targeted topical and oral antibiotic treatment. The authors conclude that Urgotul SSD has advantages of reducing pain symptom, pain medication requirement, increased patient convenience due to decreased time of follow-up at outpatient burn clinic, limiting the frequency of replacement of the dressing at comparable total cost and incidence of burn wound infection. The present study confirms the efficacy of Urgotul SSD in the treatment of partial thickness or secondary degree burn wound at the outpatient clinic.
